ImaginAb Inc. has released interim results from a Phase 2 clinical trial of IAB2M, the company's proprietary imaging agent for management of prostate cancer. IAB2M demonstrated superior performance in detecting disease compared with ProstaScint and conventional imaging technologies including computed tomography (CT) scans, magnetic resonance imaging (MRI) scans and bone scans. In addition, the agent accurately detected metastatic disease in normal-sized lymph nodes, overcoming a major limitation of existing technologies and addressing a key clinical need.
The widespread practice of incentivizing mammogram completion via cash payments, typically by insurance companies, is unethical according to a Viewpoint article published recently in JAMA by an expert from the Perelman School of Medicine at the University of Pennsylvania. Instead, incentives should be offered to women to use evidence-based decision aids to decide if they want a mammogram, even if this policy likely averts fewer breast cancer deaths overall.
September 14, 2015 — University of Arkansas for Medical Sciences (UAMS) researcher Vladimir Zharov, Ph.D., D.Sc., was ...
Clinicians and referring physicians need fast, secure access to both patient data and their diagnostic or viewing tool ...
The use of radiation therapy to treat cancer has been in existence for over a century, tracing back to the early days of ...
Navigating coverage decisions can be overwhelming and confusing, especially for high-end imaging equipment, where ...
The buzz term “big data” has made a rapid entry onto the healthcare scene in the past couple years with promises of ...
The Healthcare Information and Management Systems (HIMSS24) Conference and Exhibition (March 12-14, in Orlando, Fla.) is ...
Value-driven health platform Spreemo has completed the first phase of a study to determine how interpretative variability in magnetic resonance imaging (MRI), a standard diagnostic test, can influence the course of a patient’s treatment.
Zevacor Molecular (Zevacor), manufacturer and distributor of positron emission tomography (PET) and single photon emission computed tomography (SPECT) radiopharmaceuticals, announced the arrival of a 70 MeV Cyclotron at its new production facility in Noblesville, Indiana.
Westinghouse Electric Company and NorthStar Medical Radioisotopes announced a memorandum of understanding to explore producing medical radioisotopes from the core of commercial nuclear reactors, and methods of global distribution. The exploration involves generating the most widely used radioisotope in medical diagnostic imaging by treating an isotope of the chemical element molybdenum rather than enriched uranium.
Agfa Radiology Solutions is committed to enhancing clinical outcomes and operational efficiency, underscoring its ...
Delphinus Medical Technologies Inc. announced that it has secured a venture round of $39.5 million, the single largest amount ever raised for a healthcare imaging company in the Midwest. It is also the largest amount for a medical device company in Michigan.
Tiny gas microbubbles can enhance the delivery and absorption of cancer drugs in patients with advanced pancreatic cancer, according to a new pilot study. The study was described at the International Contrast Ultrasound Society (ICUS) annual conference in Chicago.
Women who have breast cancer on their left side present a particular challenge to radiation oncologists. Studies have ...
Playing sports is good for all ages: it helps participants stay in shape, learn how to organize their time, and help ...
The transition from film to flat panel has dramatically improved the efficiency of portable X-ray units. Transmitting ...
September 9, 2015 — The U.S. Food and Drug Administration (FDA) granted 510(k) for Philips Healthcare’s Spectral ...
Ninety-six percent of clinics and hospitals in the United States that have purchased used or refurbished medical equipment have had neutral-to-positive experiences with the purchase, according to a new survey.
More than 50 women in need received free cervical and breast cancer screenings with same-day results as part of a recent See, Test & Treat program and health fair at Loyola University Medical Center.
SRI International and DataSpeaks Inc. announced that SRI has licensed the Science of Individuality Measurement Algorithm (SIMA) software from DataSpeaks. SRI will integrate SIMA into the development of a secure enterprise system for clinical decision-making.
Varian Medical Systems is collaborating with two leading Cape Town universities to launch Africa's first 'Access to Care' program, designed to train cancer caregivers in delivering advanced conformal radiotherapy treatments.
When 64-slice computed tomography (CT) systems were introduced nearly a decade ago, they were purchased in large numbers ...